What Every Woman Should Know About Menopause and Heart Health

When a blustery storm rolls in, homeowners who prepare ahead — sealing windows, clearing the yard — come through with less damage. The same logic applies to your body: Plan ahead for changes and you can blunt their impact. For women in midlife, that storm is heart disease.

Heart disease is the leading cause of death for women in the U.S., and yet most doctors wait to treat it until cholesterol reaches dangerous levels instead of mitigating the silent shifts happening years earlier. In fact, perimenopause is now considered a critical “window of opportunity” for intervention, after a 2026 analysis of nationwide data in the Journal of the American Heart Association found that perimenopausal women are two times more likely to have a low cardiovascular health score compared to women having regular menstrual cycles.¹ Cardiovascular health scores are scientifically based measures of optimal cardiovascular health defined by the American Heart Association.

Before menopause, estrogen clears cholesterol from the blood, keeps blood vessels healthy, maintains insulin sensitivity, and regulates inflammation. When estrogen levels fluctuate in perimenopause and then plummet after menopause, those protections erode quickly and quietly, even as a basic cholesterol panel continues to look normal. 

How Declining Estrogen Impacts the Heart

Estrogen protects the heart across four different pathways, which is what makes its loss during menopause so destabilizing. 

Clears cholesterol 

HDL cholesterol — the “good” kind — pulls excess cholesterol from artery walls and transports it to the liver for disposal. Estradiol, the main form of estrogen, regulates not just how much HDL circulates in your blood, but the size and function of those particles. As estradiol falls, large, effective HDL particles give way to smaller, less capable ones. Your HDL cholesterol may still register as “normal” on a blood test, but its quality has quietly degraded. 

A similar situation happens with LDL, the so-called “bad” cholesterol, because high levels lead to plaque buildup in arteries (atherosclerosis), increasing the risk of heart disease and stroke. The steepest increases in LDL and ApoB — a protein that transports cholesterol particles from the liver and intestines to cells throughout the body — occur in the year just before and after menopause.² Higher ApoB levels means you have more plaque-driving cholesterol particles in circulation.

Keeps blood vessels healthy

Estradiol supports the endothelium — the thin inner lining of your blood vessels — keeping your artery walls supple enough to expand and contract with each heartbeat. Without that support, arteries stiffen, which makes it easier for plaque to build.

Blood moving through a flexible vessel flows smoothly, but blood moving through a rigid vessel flows turbulently, creating pressure points along the artery wall. LDL particles get caught in that turbulence and oxidize, triggering an immune response that inflames the artery wall. Inflamed arterial walls become sticky and porous, making it easier for oxidized LDL to embed and accumulate as plaque.

A study of more than 52,000 women found that estrogen loss in menopause is significantly associated with increased arterial stiffness.³

Keeps body fat distribution more cardioprotective

Before menopause, estradiol helps direct fat to the hips and thighs. As estrogen declines, fat storage shifts toward the midsection, where it’s more harmful for the heart. 

A 2021 SWAN study found that during the two years before the final menstrual period, accumulation of visceral fat — deeply embedded fat that lines abdominal walls and wraps around organs — accelerates sharply.⁴ While visceral fat makes up roughly 5–8% of total body fat premenopause, it increases to 15–20% of total body fat postmenopause.⁵ 

Visceral fat is metabolically active; it releases inflammatory signals that damage blood vessels and accelerate plaque formation. Research directly links menopause-related visceral fat accumulation to increased plaque in the arteries supplying the brain, raising the risk of both heart disease and stroke.⁶

Supports insulin sensitivity and metabolic health

Estradiol helps cells respond to insulin, keeping blood sugar stable. When estradiol levels drop, cells become less responsive. Research presented at the 2024 Menopause Society annual meeting shows that insulin resistance worsens in postmenopausal women by up to 20%.⁷ 

As cells resist insulin, the pancreas compensates by producing more of it. Chronically elevated insulin inflames arterial walls and raises blood pressure, compounding the cardiovascular damage already set in motion by shifting lipids and stiffening vessels.⁸

Keeps inflammation and blood pressure in check

Estradiol has anti-inflammatory effects that help keep blood vessel walls healthy and blood pressure stable.⁹ When it declines, many women see subtle but meaningful increases in inflammatory markers and blood pressure.

That combination is particularly damaging. Chronic inflammation makes vessel walls thicker, stiffer, and less responsive, while sustained high blood pressure forces the heart to work harder and wears down the arteries. Together, they also promote clotting, adding another pathway to heart attack and stroke risk beyond plaque alone.^{10 11}

Over time, this cumulative damage creates what cardiologists call residual coronary risk: heart attack and stroke risk that persists even in women who are on heart-protective medications like statins. 

Balances clotting and platelet activity 

Estradiol keeps platelets — small cell fragments that circulate in the blood and trigger clotting when a vessel is damaged — less likely to clump together unnecessarily, so blood flows smoothly through your arteries.¹² As estradiol falls, platelets become more reactive, and the clotting system grows more reactive overall.

Clots that form on top of arterial plaque can abruptly cut off blood supply to the heart or brain, causing a heart attack or stroke.

Declining estrogen also thickens the blood itself, reducing circulation efficiency, a compounding effect on top of increased platelet reactivity. Together, these shifts help explain why stroke rates double in women between their late forties and early sixties.¹³

What Midlife Women Should Be Screened For

Midlife heart screening needs to look at the systems affected by estrogen loss before silent risk becomes irreversible disease. For women in perimenopause and early postmenopause, that means adding these vital screenings to the standard cholesterol check:

• Lipoprotein(a). This genetic marker, which you need to check only once, measures a sticky, inflammation-promoting form of LDL that’s an independent risk factor for heart disease. Lp(a) levels rise after menopause by 20–30% but can be lowered with hormone therapy.¹⁴
• Hematocrit. This marker measures the proportion of red blood cells in the blood. Higher levels mean thicker blood. Elevated hematocrit can signal reduced circulation efficiency and increased clotting risk.
• Blood pressure. Sustained rises over time, even within the “normal” range, can suggest blood vessel stiffening and warrant deeper cardiac evaluation.
• Hot flash frequency and duration. Women whose hot flashes persist across four or more annual checkups have a measurably increased cardiovascular risk.¹⁵ Studies have linked persistent hot flashes to stiffer arteries, which often lead to plaque buildup.¹⁶  

Although estrogen decline is a key driver of heart risk in midlife, testing its levels will not provide meaningful information about what’s happening with your heart. That’s partly because estrogen levels at midlife fluctuate too widely to be considered definitive, and also because there’s no established threshold that predicts cardiovascular risk. It’s also true that two women with the same estrogen levels can still have very different heart risk profiles depending on their genetics, timing, lifestyle, and which of their systems are under the most stress. 

Heart Protection After Menopause

For many women, HRT can restore estrogen to levels that significantly reduce the factors driving heart disease, particularly when initiated at the right time and under the right conditions. Benefits depend on:

Your age

HRT is most effective at lowering the risk of coronary heart disease and death when started before age 60 or within 10 years of menopause.¹⁷ In the large-scale Women’s Health Initiative study, women aged 50–59 years who received estrogen-only HRT had a 40% reduced risk of heart attack compared to those who received a placebo.¹⁸

After 60, the risk-benefit equation shifts. Some cardiovascular risks rise with age and time since menopause, which is why decisions made later require more individualized assessment.¹⁹

Time since menopause onset

Starting HRT close to menopause — when vessels are still responsive and plaque is minimal — allows estradiol to work with relatively healthy tissue. A 2016 study found that estradiol slowed early plaque buildup when started within six years of menopause, but not when started a decade later.²⁰ The longer the gap between menopause and HRT, the less cardiovascular benefit HRT may offer, which is why perimenopause testing is an important step in cardiac care.

Formulation and delivery route

The formulation of HRT affects how estradiol is metabolized and which risks it carries. Oral estrogen is processed through the liver, which can raise triglycerides (fats in your blood that, when elevated, can build up in artery walls and increase heart disease risk) and clotting factors in some women. Transdermal delivery — patches, gels, creams — bypasses the liver entirely, which may offer a more favorable cardiovascular and clotting profile for many patients.

Bioidentical versus synthetic formulations, and whether you take estrogen alone or estrogen plus progesterone, add further nuance. Work with a physician who understands the full range of options and can match the formulation to your specific risk profile, not just your symptoms.

Individual risk factors

Whether HRT is appropriate — and which formulations make sense — depend on your personal health history. Have a risk-benefit conversation with your doctor if you have a history of any of these conditions:

• Breast cancer. HRT has long been considered off-limits for women with a breast cancer history out of fear that it could drive recurrence. Newer research has some physicians rethinking HRT after breast cancer, particularly for certain cancer types and formulations. 
• Blood clotting disorders. Some clotting conditions increase the risk of deep vein thrombosis or pulmonary embolism with certain HRT formulations, particularly oral estrogen. Transdermal HRT can carry a lower clotting risk for some women.
• History of stroke or heart attack. Women with existing cardiovascular disease require individualized assessment rather than a standard protocol.
• Gallbladder or liver disease. The liver processes oral estrogen, which can affect gallbladder function. Transdermal formulations bypass this pathway and may be better tolerated.²¹

Hone’s Approach to Heart Protection After Menopause

Hone physicians go beyond standard cholesterol testing to measure 50+ biomarkers, assessing how estrogen loss is affecting arterial inflammation, metabolic health, liver function, and hormones together. The goal is to identify the highest-priority risk and treat it first; then address the next layer of care until risk across all four systems is under control.

When HRT is part of the plan, it’s matched to the patient’s biomarker profile, risk factors, and timing relative to menopause.

Hone also emphasizes healthy lifestyle habits. Strength training, aerobic activity, sleep quality, and diet all directly influence ApoB, blood pressure, and insulin resistance, the same markers driving cardiovascular risk. 

Real Science, Real Results

Get expert insights on fueling your body, supporting metabolism, and living longer—delivered to your inbox every Monday.

"*" indicates required fields

Name*

Email*

Subscribe to*

Hone In: Men’s health, performance, and longevity

Hone Your Life: Women’s health, hormones, and well-being

Join The Hone Newsletter

About the author

Dr. Abid Husain is a Consulting Physician and Scientific Advisor for Hone Health. As a triple-board-certified cardiologist and integrative medicine physician, Dr. Husain combines his background in traditional cardiology with functional medicine to offer a unique, multi-faceted modality of care.